SOURCE: Bio-Rad Laboratories

January 28, 2010 20:29 ET

Bio-Rad Laboratories, Inc. Announces Extension of Exchange Offer

HERCULES, CA--(Marketwire - January 28, 2010) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced today that its pending offer to exchange (the "Exchange Offer") any and all of its outstanding 8.00% Senior Subordinated Notes due 2016 that were issued in a private placement (the "Private Notes") for 8.00% Senior Subordinated Notes due 2016 that have been registered under the Securities Act of 1933, as amended, currently scheduled to expire at 5:00 p.m., New York City time, on January 28, 2010, has been extended until 5:00 p.m., New York City time, on February 4, 2010.

Tenders with respect to approximately $299,980,000 aggregate principal amount of the Private Notes, out of a total of $300,000,000 aggregate principal amount eligible to participate in the Exchange Offer, have been received to date.

This announcement is not an offer to exchange, or a solicitation of an offer to exchange, with respect to the Private Notes. The Exchange Offer is being made solely by the prospectus dated December 29, 2009, and the Exchange Offer, as extended hereby, remains subject to the terms and conditions stated therein.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The Company employs over 6,700 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

Contact Information

  • For more information contact:
    Christine Tsingos
    Vice President and Chief Financial Officer
    Ron Hutton
    Bio-Rad Laboratories, Inc.
    Email Contact